Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: The rifaximin and eluxadoline clinical development programs for IBS-D have demonstrated significant improvement in IBS-D endpoints compared to placebo. Direct comparison of primary endpoint results from the alosetron, rifaximin, and eluxadoline pivotal trials is not possible; however, general estimates of efficacy can be made, and these demonstrate similar and significantly greater responses to 'adequate relief' and a composite endpoint of abdominal pain/stool form for each agent compared to placebo. With the recent approval in the United States of rifaximin and eluxadoline for IBS-D, how should clinicians employ these agents? We suggest that they be utilized sequentially, taking into consideration patient symptoms and severity, prior medical history, mode of action, cost, availability, managed care coverage, and adverse event profiles.
|
Authors | Brooks D Cash, Brian E Lacy, Tharaknath Rao, David L Earnest |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 17
Issue 3
Pg. 311-22
( 2016)
ISSN: 1744-7666 [Electronic] England |
PMID | 26559529
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Carbolines
- Gastrointestinal Agents
- Imidazoles
- Narcotic Antagonists
- Receptors, Opioid
- Rifamycins
- Serotonin 5-HT3 Receptor Antagonists
- alosetron
- eluxadoline
- Phenylalanine
- Rifaximin
|
Topics |
- Abdominal Pain
(drug therapy, physiopathology)
- Anti-Bacterial Agents
(therapeutic use)
- Carbolines
(therapeutic use)
- Diarrhea
(drug therapy, physiopathology)
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Imidazoles
(therapeutic use)
- Irritable Bowel Syndrome
(drug therapy, physiopathology)
- Narcotic Antagonists
(therapeutic use)
- Phenylalanine
(analogs & derivatives, therapeutic use)
- Receptors, Opioid
(agonists)
- Rifamycins
(therapeutic use)
- Rifaximin
- Serotonin 5-HT3 Receptor Antagonists
(therapeutic use)
|